Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, a monoclonal antibody that stimulates the 4-1BB receptor on T cells and NK cells in the tumor, which is in phase 1 for the treatment of solid metastatic cancers. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; BioArctic AB; and Abclon Inc. The company was incorporated in 2000 and is headquartered in Lund, Sweden.
तुलना करने के लिए मीट्रिक्स | ATORX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधATORXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −1.3x | −2.3x | −0.5x | |
PEG अनुपात | −0.01 | −0.08 | 0.00 | |
क़ीमत/बुक | −11.0x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2.2x | 9.1x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 266.7% | 130.2% | 45.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 11.6% | 5.1% | अनलॉक करें |